Antibodies

Moncef Zouali, University René Diderot Paris 7, F‐75475 Paris, France

Published online: June 2010

DOI: 10.1002/9780470015902.a0000906.pub2

The immune system is able to generate a large repertoire of antibodies capable of recognising virtually all possible antigens present in the environment. An antibody is a Y-shaped tetrameric protein characteristically composed of two heavy (H) and two light (L) polypeptide chains held together by covalent (disulfide) and noncovalent bonds. Each antibody chain is composed of a constant and a variable region, and its specificity is characterised by the uniqueness of its variable regions and the pairing of its H and L chains. At the three-dimensional level, hypervariable regions of each chain converge to form a combining site that recognises antigenic determinants. Antibodies bind their nominal antigens with exquisite specificity and potentially neutralise their harmful effects, providing a first line of defence against pathogens. Rather than playing a protective role, certain antibodies may be responsible for undesirable functions, such as enhancing the infectious potential of pathogens or mediating hypersensitivity and autoimmune reactions.

Key Concepts:

  • Each B lymphocyte is committed to the synthesis of one antibody specifically characterised by the uniqueness of its variable regions and the pairing of its heavy and light chains.
  • With antigen stimulation, B cells proliferate, differentiate and may recombine another constant exon, giving rise to IgG, IgA or IgE antibodies. This process, called isotype switching or class switching, enables antibodies of a given specificity to acquire a different constant region and, hence, to change their effector function.
  • In humans, five classes of immunoglobulins, also called isotypes (IgG, IgM, IgA, IgD and IgE), differ in their physicochemical and serological properties, and the amino acid sequence of their constant regions. There are four subclasses of IgGs (IgG1–IgG4) and two subclasses of IgAs (IgA1 and IgA2).
  • Secondary antibodies are dominated by IgG of higher affinity for the immunogen than the primary IgM. Persistence of memory lymphocytes for many years provides the recipient with a potential long-lasting protection against the invader and allows successful vaccination and prevention against pathogens.
  • An antibody is a Y-shaped tetrameric protein characteristically composed of two heavy and two light polypeptide chains held together by covalent (disulfide) and noncovalent bonds. Each antibody chain is composed of a constant and a variable region.
  • At the three-dimensional level, hypervariable regions of each chain converge to form a combining site that recognises antigenic determinants. Electrostatic forces between charged amino acid side-chains, hydrogen bonds, Van der Waals forces and hydrophobic forces, together with surface complementarity, impart antibody-specific recognition.
  • The immune system is able to generate a large repertoire of antibodies able to recognise virtually all possible antigens present in pathogens and their products (bacteria, viruses and protozoal and metazoal parasites), and in the environment.
  • Antibodies secreted by B lymphocytes are responsible for the humoral immune response which plays a critical role in destruction of extracellular pathogens, prevention against the spread of intracellular infections and protection against toxins. The two structural portions of the antibody, that is the variable (Fab) and the constant (Fc) fragments, impart distinct biological functions.
  • Antibodies can contribute to elimination of undesirable cells by recruiting killer cells, a mechanism used to clear pathogen-infected cells.
  • Rather than playing a protective role, antibodies may be responsible for undesirable functions, such as enhancing the infectious potential of certain infectious agents or mediating hypersensitivity reactions.

Keywords: humoral immune response; immune protection; immunoglobulins; B lymphocytes; isotypes

Figure 1. Diagram of a prototypic immunoglobulin IgG monomer. Each rectangle represents an immunoglobulin domain. The CDRs are highlighted. The dark bars depict the Hinge region. Fc fragment (for ‘fragment crystalline’): Fragment produced by papain digestion of IgG that can be crystallised from a solution. It is the anchoring site for proteins of the complement system and for receptors of various effector cells. Fab fragment (for ‘fragment antigen binding’): Fragment produced by papain digestion of IgG. It possesses one combining site and can bind, but cannot precipitate, the antigen. F(ab¢)2 fragment: Fragment produced by pepsin digestion of IgG. Its molecular weight is double that of one Fab fragment, and it is capable of binding and precipitating the antigen.
Figure 2. Digestion of immunoglobulins with papain and pepsin. Digestion with papain breaks the immunoglobulin molecule in the hinge region before the H–H interchain disulfide bond. This results in the formation of two identical fragments, called Fab, that contain the L chain, and the VH and CH1 domains of the H chain. It also gives rise to the Fc fragment composed of two H chains containing a CH2 and a CH3 domain. Pepsin treatment of immunoglobulins cleaves the H chain after the H–H inter chain disulfide bonds, resulting in a bivalent fragment that contains two antigen binding sites, called F(ab¢)2. The Fc region of the immunoglobulin is digested into small fragments by pepsin.
close
 Further Reading
    Bouvet JP and Zouali M (2005) Silent antibodies. Archives de l'Institut Pasteur de Tunis 82: 3–8.
    Braden B and Poljak R (1995) Structural features of the reactions between antibodies and protein antigens. FASEB Journal 9: 9–16.
    James LC, Roversi P and Tawfik DS (2003) Antibody multispecificity mediated by conformational diversity. Science 299: 1362–1367.
    Jerne N (1985) The generative grammar of the immune system. Science 229: 1057–1059.
    Kaneko Y, Nimmerjahn F and Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670–673.
    Kozyr AV and Gabibov AG (2009) DNA-hydrolyzing Ab: is catalytic activity a clue for physiological significance? Autoimmunity 42: 359–361.
    Lim PL and Zouali M (2006) Pathogenic autoantibodies: emerging insights into tissue injury. Immunology Letters 103: 17–26.
    Milstein C (1993) From the structure of antibodies to the diversification of the immune response. Scandinavian Journal of Immunology 37: 385–398.
    van der Neut Kolfschoten M, Schuurman J, Losen M et al. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554–1557.
    Nimmerjahn F and Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510–1512.
    Ohlin M and Zouali M (2003) The human antibody repertoire to infectious agents: implications for disease pathogenesis. Molecular Immunology 40: 1–11.
    Rajewsky K (1996) Clonal selection and learning in the antibody system. Nature 381: 751–758.
    Saerens D, Ghassabeh GH and Muyldermans S (2008) Single-domain antibodies as building blocks for novel therapeutics. Current Opinion in Pharmacology 8: 600–608.
    Torres M, Fernandez-Fuentes N, Fiser A and Casadevall A (2007) The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. Journal of Biological Chemistry 282: 13917–13927.
    Wentworth P and Janda K (1998) Catalytic antibodies. Current Opinion in Chemical Biology 2: 138–144.
    Wilson I and Stanfield R (1994) Antibody-antigen interactions: new structures and new conformational changes. Current Opinion in Structural Biology 4: 857–867.
    Zouali M (1994) Unravelling antibody genes. Nature Genetics 7: 118–120.
    Zouali M (2007) B cell superantigens subvert innate functions of B cells. Chemical Immunology and Allergy 93: 92–105.
    Zouali M (2007) Exploitation of host signaling pathways by B cell superantigens – potential strategies for developing targeted therapies in systemic autoimmunity. Signal Transduction Pathways, Part C 1095: 342–354.
    Zouali M and Hansen DE (1994) Antibodies–no longer just for binding. Trends in Biotechnology 12: 73–74.

Related Sub-Topics:

Antibodies | Proteins: Structure, Function, Metabolism
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Antibodies
 
How to Cite close
Zouali, Moncef(Jun 2010) Antibodies. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0000906.pub2]